February 3, 2022 News by Marisa Wexler, MS Self-injectable Therapies Tied to No Disease in 50% of Patients at 2 Years More than half of multiple sclerosis (MS) patients treated with self-injectable therapies — namely, glatiramer acetate, marketed as Copaxone, among others, or any of a host of interferons — showed no evidence of disease activity after two years, according to a study out of Turkey. Among patients treated for…
July 8, 2021 News by Patricia Inacio, PhD Sativex Eased MS Spasticity as an Add-on Therapy Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or…
March 31, 2021 News by Patricia Inacio, PhD In Real World, Tysabri Lessens Disease Activity, Reduces Relapses in Pediatric-onset MS Off-label treatment with Tysabri (natalizumab) significantly lessens disease activity and reduces the number of relapses per year in patients with pediatric-onset multiple sclerosis (POMS), real-world data from Portugal show. The treatment also was considered safe in this population, in agreement with earlier studies. These findings support the usefulness…
March 19, 2021 News by Margarida Maia, PhD Ocrevus May Delay by 7 Years PPMS Patients’ Need for Wheelchair Ocrevus (ocrelizumab) treatment may delay the need for a wheelchair by seven years in patients with primary progressive multiple sclerosis (PPMS), a study reports. This delay, drawn from clinical trial data on treatment- versus placebo-group patients and supported by real-world findings, likely translates to long-term benefits for PPMS patients,…
September 14, 2020 News by Marta Figueiredo, PhD #MSVirtual2020 – Early Intensive DMT Use in RRMS Appears More Effective Than Escalation Early use of high efficacy disease-modifying therapies (DMTs) is more effective than the traditional approach — that of an escalating treatment regimen — at delaying disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study from Italy reports. People later moving to more aggressive treatment also appeared…
November 1, 2019 News by Ana Pena PhD Interferons Superior to Glatiramer Acetate, and Tysabri More Effective than Gilenya for RRMS, Real-world Study Finds Interferon therapy (brand names Avonex, Betaseron, and others) is more effective than glatiramer acetate (sold as Copaxone, Glatopa and other generics) for reducing relapses…
September 12, 2019 News by Joana Carvalho, PhD #ECTRIMS2019 — Biogen Presents New Real-world Data Demonstrating Clinical Benefits of Tysabri, Plegridy, and Avonex Biogen is presenting new data highlighting the potential clinical benefits of Tysabri (natalizumab), Plegridy (peginterferon beta-1a), and Avonex (interferon beta-1a) for the treatment of specific groups of individuals with multiple sclerosis (MS), including pregnant women and patients with relapsing forms of the disease. The new…
April 11, 2019 News by Patricia Inacio, PhD Tecfidera Better at Preventing Relapses than Aubagio, Real-world Study Suggests Tecfidera (dimethyl fumarate) is more efficient at preventing relapses, and has a lower discontinuation rate than Aubagio (teriflunomide), according to a Danish study. The study “Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study” was published in the journal Neurology. Aubagio (marketed by Sanofi Genzyme) and Tecfidera…
March 1, 2019 News by Jonathan Grinstein #ACTRIMS2019 — Use of Ocrevus at Cleveland Clinic Backs Phase 3 Trial Data Ocrevus (ocrelizumab) was shown to be a highly effective therapy for people with multiple sclerosis (MS) in real-world clinical practice, according to Brandon Moss, MD, from the Cleveland Clinic. The data was presented in a poster session Feb. 28, at the Americas Committee…
February 22, 2019 News by Jonathan Grinstein Aubagio, Tecfidera Show Comparable Effectiveness in Relapsing MS, Real-world Phase 4 Trial Finds Aubagio (teriflunomide) seems to be superior to Tecfidera (dimethyl fumarate) in slowing whole brain shrinkage in patients with relapsing multiple sclerosis (MS), a new Phase 4 clinical trial shows. However, Aubagio and Tecfidera have similar beneficial effects in achieving other clinical goals and magnetic resonance imaging (MRI) parameters,…
October 27, 2017 News by Patricia Silva, PhD #MSParis2017 – Real-world Data Leading Way to Personalized Treatment, Biogen Says in Interview Personalized medicine is the future of multiple sclerosis treatment, and research now taking place to collect and analyze data and pinpoint biomarkers will help make possible approaches that — one day — will put MS into “complete remission” patient by patient, said Richard Rudick, vice president of Development Sciences at…
